Press Releases



Mediclinic Intnl plc - Directorate Change

24/05/2018
RNS Number : 1022P
Mediclinic International plc
24 May 2018
 

 

 

 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

 

24 May 2018

 

Chief Executive Officer to continue as a Non-executive Director

 

Mediclinic, a leading international private healthcare services group, announces that on 23 May 2018, the Board agreed that, subject to Mr Danie Meintjes're-election as a director of the Company at the Annual General Meeting to be held on 25 July 2018, he will continue to serve as an executive director until 31 July 2018 and as a non-executive director with effect from 1 August 2018. As previously announced on 29 March 2018, Dr Ronnie van der Merwe will succeed Mr Meintjes as Chief Executive Director on 1 June 2018.

 

 

Mediclinic's chairman, Dr Edwin Hertzog commented:

"Danie's continued role as a non-executive director of the Company after his retirement as CEO was made after careful consideration by the Nomination Committee and the Board. This appointment is considered to be in the long-term interest of Mediclinic, its shareholders and other stakeholders in view of the wealth of knowledge and experience Danie has gained in different capacities over 30 years at Mediclinic."

 

 

NOTES TO EDITORS

About Danie Meintjes

Mr Meintjes (aged 61) joined the group in 1985 as the Hospital Manager of Mediclinic Sandton before being appointed head of Human Resources and Training for the Mediclinic Group. He subsequently became a member of Mediclinic International Limited's Executive Committee in 1995 and a director in 1996. Seconded to the Mediclinic's operations in Dubai in 2006 and appointed as the Chief Executive Officer of Mediclinic Middle East in 2007, he was named Chief Executive Officer of Mediclinic International Limited in 2010. Following the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited, Mr Meintjes continued to serve as the Chief Executive Officer of the enlarged group since February 2016.

 

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

 

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.

 

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

 

For further information, please contact:

 

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

 

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com 

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGUBUAUPRGBW